1. Rana S, Lemoine E, Granger JP, et al. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124(7):1094-1112.
2. Kajantie E, Eriksson JG, Osmond C, et al. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009;40(4):1176-1180.
3. Bellamy L, Casas JP, Hingorani AD, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
4. Sugawara J, Oe Y, Wagata M. Genetic Background of Preeclampsia. In: Saito S. (eds) Preeclampsia. Comprehensive Gynecology and Obstetrics. Springer, Singapore. 2018; 29-43.
5. Gray KJ, Saxena R, Karumanchi SA. Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis. Am J Obstet Gynecol. 2018;218(2):211-218.
6. Yong HEJ, Murthi P, Brennecke SP, Moses EK. Genetic Approaches in Preeclampsia. Methods Mol Biol. 2018;1710:53-72.
7. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534-543.
8. Saito S, Sakai M, Sasaki Y,et al. Inadequate tolerance induction may induce pre-eclampsia. J Reprod Immunol. 2007;76(1-2):30-39.
9. Oyarzo C, Bertoglia P, Avendaño R, et al. Adverse perinatal outcomes after the February 27th 2010 Chilean earthquake. J Matern Fetal Neonatal Med. 2012;25(10):1868-1873.
10. 有馬隆博. 大規模災害後の宮城県妊婦のメンタルヘルスと 胎児，新生児への健康影響に関するゲノムコホート研究, 大和証券, 大和証券ヘルス財団研究業績集, Vol 36, (公財)大和証券ヘルス財団, 東京都, 2012; 143-147.
11. Auger N, Duplaix M, Bilodeau-Bertrand M, et al. Environmental noise pollution and risk of preeclampsia. Environ Pollut. 2018;239:599-606.
12. Chaiworapongsa T Chaemsaithong P, Yeo L, et al. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014 ;10(8):466-80.
13. Boeldt DS, Bird IM. Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. J Endocrinol. 2017;232(1):R27-r44.
14. Mercy PrabhuDas, Elizabeth Bonney, Kathleen Caron, et al. Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nat Immunol.. 2015 Apr;16(4):328-34.
15. Sammar M, Siwetz M, Meiri H, et al. Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetal-maternal interface. Histochem Cell Biol. 2017;147(5):565-574.
16. La Rocca C, Carbone F, Longobardi S, et al. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett. 2014;162(1 Pt A):41-48.
17. Hiby SE, Walker JJ, O'Shaughnessy K M, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200(8):957-965.
18. Piccinni MP. T cell tolerance towards the fetal allograft. J Reprod Immunol. 2010;85(1):71-75.
19. Takakuwa K, Arakawa M, Tamura M, et al. HLA antigens in patients with severe preeclampsia. J Perinat Med. 1997;25(1):79-83.
20. Ooki I, Takakuwa K, Akashi M,et al. Studies on the compatibility of HLA-Class II alleles in patient couples with severe pre-eclampsia using PCR-RFLP methods. Am J Reprod Immunol. 2008;60(1):75-84.
21. Hoff C, Peevy K, Giattina K, et al. Maternal-fetal HLA-DR relationships and pregnancyinduced hypertension. Obstet Gynecol. 1992;80(6):1007-1012.
22. Biggar RJ, Poulsen G, Ng J, et al. HLA antigen sharing between mother and fetus as a risk factor for eclampsia and preeclampsia. Hum Immunol. 2010;71(3):263-267.
23. Triche EW, Harland KK, Field EH, et al. Rubenstein LM, Saftlas AF. Maternal-fetal HLA sharing and preeclampsia: variation in effects by seminal fluid exposure in a case-control study of nulliparous women in Iowa. J Reprod Immunol. 2014;101-102:111-119.
24. Tersigni C, Redman CW, Dragovic R, et al. HLA-DR is aberrantly expressed at fetomaternal interface in pre-eclampsia. J Reprod Immunol. 2018;129:48-52.
25. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol. 2008;29(7):313-321.
26. Apps R, Murphy SP, Fernando R, et al. Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies. Immunology. 2009;127(1):26-39.
27. 昭子 石. HLA-E,HLA-G 、 HLA-F の発現と機能. - 胎児 / 母体間免疫のブラックボックスは開きうるか -. Vol Vol.53. Journal of Nara Medical Association 2002.
28. Wang YQ, Chen SL, Xing FQ. Expression of HLA-G protein in trophoblast cells. Di Yi Jun Yi Da Xue Xue Bao. 2005;25(12):1488-1490.
29. Rajagopalan S, Long EO. Cell atlas reveals the landscape of early pregnancy. Nature. Vol 563. England2018.
30. Vento-Tormo R, Efremova M, Botting RA, et al. Single-cell reconstruction of the early maternal-fetal interface in humans. Nature. 2018;563(7731):347-353.
31. Ander SE, Diamond MS, Coyne CB. Immune responses at the maternal-fetal interface. Sci Immunol. 2019;4(31).
32. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999;189(7):1093-1100.
33. Apps R, Gardner L, Sharkey AM, et al. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol. 2007;37(7):1924-1937.
34. Chumbley G, King A, Robertson K, et al. Resistance of HLA-G and HLA-A2 transfectants to lysis by decidual NK cells. Cell Immunol. 1994;155(2):312-322.
35. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A. 1987;84(24):9145-9149.
36. Stewart CA, Horton R, Allcock RJ, et al. Complete MHC haplotype sequencing for common disease gene mapping. Genome Res. 2004;14(6):1176-1187.
37. Shiina T, Ota M, Shimizu S, et al. Rapid evolution of major histocompatibility complex class I genes in primates generates new disease alleles in humans via hitchhiking diversity. Genetics. 2006;173(3):1555-1570.
38. Pankratz S, Ruck T, Meuth SG, et al. CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance. Hum Immunol. 2016;77(9):727-733.
39. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 2000;164(12):6100-6104.
40. Fuzzi B, Rizzo R, Criscuoli L, et al. HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol. 2002;32(2):311-315.
41. Farina A, Zucchini C, De Sanctis P, et al. Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre-eclampsia later in pregnancy: implications for screening. Prenat Diagn. 2011;31(2):181-185.
42. Hylenius S, Andersen AM, Melbye M, et al. Association between HLA-G genotype and risk of pre-eclampsia: a case-control study using family triads. Mol Hum Reprod. 2004;10(4):237-246.
43. Rokhafrooz S, Ghadiri A, Ghandil P, et al. Association between HLA-G 14 bp Gene Polymorphism and Serum sHLA-G Protein Concentrations in Preeclamptic Patients and Normal Pregnant Women. Immunol Invest. 2018;47(6):558-568.
44. Mandò C, Pileri P, Mazzocco MI, et al. Maternal and fetal HLA-G 14 bp gene polymorphism in pregnancy-induced hypertension, preeclampsia, intrauterine growth restricted and normal pregnancies. J Matern Fetal Neonatal Med. 2016;29(9):1509-1514.
45. Pabalan N, Jarjanazi H, Sun C, et al. Meta-analysis of the human leukocyte antigen-G (HLA-G) 14 bp insertion/deletion polymorphism as a risk factor for preeclampsia. Tissue Antigens. 2015;86(3):186-194.
46. Ferreira LC, Lopes TPB, Guimarães TB, et al. The maternal 14 bp Ins/Del polymorphism in HLA-G is not associated with preeclampsia risk. Int J Immunogenet. 2017;44(6):350-355.
47. Larsen MH, Hylenius S, Andersen AM, Hviid TV. The 3'-untranslated region of the HLAG gene in relation to pre-eclampsia: revisited. Tissue Antigens. 2010;75(3):253-261. 2010.
48. Konrad J Karczewski, Laurent C Francioli, Grace Tiao, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443.
49. Tadaka S, Katsuoka F, Ueki M, et al. 3.5KJPNv2: an allele frequency panel of 3552 Japanese individuals including the X chromosome. Hum Genome Var. 2019;6:28.
50. Kazuyoshi Hosomichi, Takashi Shiina, Atsushi Tajima, et al. The impact of nextgeneration sequencing technologies on HLA research. J Hum Genet. 2015;60(11):665-73.
51. Rhoads A, Au KF. PacBio Sequencing and Its Applications. Genomics Proteomics Bioinformatics. 2015;13(5):278-289.
52. NGS / de novo ゲノム解析 (PacBio RSII)のサイトより抜粋 (URL：https://eurofinsgenomics.jp/jp/service/ngs/denovo_genome_pacbiors2/) 最終アクセス日：2021/1/25
53. 次世代シーケンス 受託サービス キャンペーンのサイトより抜粋 (URL：https://bio.integrale.co.jp/pdf/202011s1.pdf) 最終アクセス日：2021/1/25
54. Kuriyama S, Metoki H, Kikuya M, et al. Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): rationale, progress and perspective. Int J Epidemiol. 2020;49(1):18-19m.
55. Gynecologists ACoOa, Pregnancy TFoHi. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122-1131.
56. Minegishi N, Nishijima I, Nobukuni T, et al. Biobank Establishment and Sample Management in the Tohoku Medical Megabank Project. Tohoku J Exp Med. 2019;248(1):45-55.
57. Wang WY, Tian W. Identification of a new HLA-G allele, HLA-G*01:19, by cloning and phasing. Int J Immunogenet. 2016;43(4):242-243.
58. Dias FC, Bertol BC, Poras I, et al. The genetic diversity within the 1.4kb HLA-G 5' upstream regulatory region moderately impacts on cellular microenvironment responses. Sci Rep. 2018;8(1):5652.
59. Suzuki S, Ranade S, Osaki K, et al. Reference Grade Characterization of Polymorphisms in Full-Length HLA Class I and II Genes With Short-Read Sequencing on the ION PGM System and Long-Reads Generated by Single Molecule, Real-Time Sequencing on the PacBio Platform. Front Immunol. 2018;9:2294.
60. Cereb N, Kim HR, Ryu J,et al. Advances in DNA sequencing technologies for high resolution HLA typing. Hum Immunol. 2015;76(12):923-927.
61. HLA タイピング結果のアレル表記法と結果報告の原則: 日本組織適合性学会 HLA 標準化委員会 2017.
62. Altschul SF, Gish W, Miller W, Myers EW, et al. Basic local alignment search tool. J Mol Biol. 1990;215(3):403-410.
63. Yamashita T, Fujii T, Watanabe Y, et al. HLA-G gene polymorphism in a Japanese population. Immunogenetics. 1996;44(3):186-191.
64. Ishitani A, Kishida M, Sageshima N, et al. Re-examination of HLA-G polymorphism in African Americans. Immunogenetics. 1999;49(9):808-811.
65. Tadaka S, Saigusa D, Motoike IN, et al. jMorp: Japanese Multi Omics Reference Panel. Nucleic Acids Res. 2018;46(D1):D551-d557.
66. Willems T, Gymrek M, Highnam G, et al. The landscape of human STR variation. Genome Res. 2014;24(11):1894-1904.
67. Gymrek M, Willems T, Reich D, et al. Interpreting short tandem repeat variations in humans using mutational constraint. Nat Genet. 2017;49(10):1495-1501.
68. John Lonsdale, Jeffrey Thomas, Mike Salvatore, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-585.
69. Dahl M, Djurisic S, Hviid TV. The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy. J Immunol Res. 2014;2014:591489.
70. Holbrook JA, Neu-Yilik G, Hentze MW, et al. Nonsense-mediated decay approaches the clinic. Nat Genet. 2004;36(8):801-808.
71. Roy-Engel AM, Salem AH, Oyeniran O Oyeniran,, et al. Active Alu element "A-tails": size does matter. Genome Res. 2002;12(9):1333-1344.
72. Hayden KM, McEvoy JM, Linnertz C, et al. A homopolymer polymorphism in the TOMM40 gene contributes to cognitive performance in aging. Alzheimers Dement. 2012;8(5):381-388.
73. Prokopenko I, Miyakawa G, Zheng B, et al. Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE-ε4/TOMM40 long poly-T repeat allele variants. Alzheimers Dement (N Y). 2019;5:814-824.
74. Linnertz C, Saunders AM, Lutz MW, et al. Characterization of the poly-T variant in the TOMM40 gene in diverse populations. PLoS One. 2012;7(2):e30994.
75. Mayor NP, Robinson J, McWhinnie AJ, et al. HLA Typing for the Next Generation. PLoS One. 2015;10(5):e0127153.
76. Hayward DR, Bultitude WP, Mayor NP,et al. The novel HLA-B*44 allele, HLA-B*44:220, identified by Single Molecule Real-Time DNA sequencing in a British Caucasoid male. Tissue Antigens. 2015;86(1):61-63.
77. Chen J, Xing C, Zheng X, et al. Functional Genomic Identification of Cadmium Resistance Genes from a High GC Clone Library by Coupling the Sanger and PacBio Sequencing Strategies. Genes (Basel). 2019;11(1).
78. Bae SC, Lee YH. Association of HLA-G polymorphisms with systemic lupus erythematosus and correlation between soluble HLA-G levels and the disease: a meta-analysis. Z Rheumatol. 2020.
79. Gautam S, Kumar U, Kumar M,et al. Association of HLA-G 3'UTR Polymorphisms with Soluble HLA-G Levels and Disease Activity in Patients with Rheumatoid Arthritis: A CaseControl Study. Immunol Invest. 2020;49(1-2):88-105.
80. Wiśniewski A, Kowal A, Wyrodek E, et al. Genetic polymorphisms and expression of HLAG and its receptors, KIR2DL4 and LILRB1, in non-small cell lung cancer. Tissue Antigens. 2015;85(6):466-475.
81. Jiang Y, Li W, Lu J, et al. HLA-G +3142 C>G polymorphism and cancer risk: Evidence from a meta-analysis and trial sequential analysis. Medicine (Baltimore). 2019;98(25):e16067.
82. Ouni N, Chaaben AB, Kablouti G, et al. The Impact of HLA-G 3'UTR Polymorphisms in Breast Cancer in a Tunisian Population. Immunol Invest. 2019;48(5):521-532.
83. Janssen M, Thaiss F, Nashan B, et al. Donor derived HLA-G polymorphisms have a significant impact on acute rejection in kidney transplantation. Hum Immunol. 2019;80(3):176-183.
84. Adamson MB, Di Giovanni B, Ribeiro RVP, et al. HLA-G +3196 polymorphism as a risk factor for cell mediated rejection following heart transplant. Hum Immunol. 2020;81(4):134-140.
85. Munster VJ, Koopmans M, van Doremalen N et al. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020;382(8):692-694.
86. Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619-1629.
87. Islam KU, Iqbal J. An Update on Molecular Diagnostics for COVID-19. Front Cell Infect Microbiol. 2020 Nov 10; 10:560616.
88. Zhang S, Gan J, Chen BG, et al. Dynamics of peripheral immune cells and their HLA-G and receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence. Clin Transl Immunology. 2020;9(5): e1128.
89. Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020 Jun;53(3):425-435.
90. Remy KE, Mazer M, Striker DA, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight . 2020; 5(17):e140329.
論文の公開元へ
